NCT03937414

Brief Summary

One-step Nucleic Acid Amplification assay (the OSNA assay) (Sysmex, Kobe, Japan) was an objective molecular technique that combines node tissue homogenization and subsequent reverse-transcription loop-mediated isothermal amplification of CK-19 mRNA in a single quick step. In the study, the performance of the OSNA assay was compared with the present standard histological evaluation, and a comparative analysis of OSNA assay with Touch Imprint Cytology (TIC) was also been made.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,500

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Feb 2010

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2010

Completed
9.2 years until next milestone

First Submitted

Initial submission to the registry

April 27, 2019

Completed
6 days until next milestone

First Posted

Study publicly available on registry

May 3, 2019

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2020

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2020

Completed
Last Updated

May 3, 2019

Status Verified

May 1, 2019

Enrollment Period

10 years

First QC Date

April 27, 2019

Last Update Submit

May 2, 2019

Conditions

Keywords

Breast neoplasm; Molecular Diagnostic Techniques

Outcome Measures

Primary Outcomes (1)

  • The accuracy, sensitivity, specificity of the OSNA assay

    The accuracy, sensitivity, specificity of the OSNA assay

    10 years

Study Arms (1)

SLNs were tested by the OSNA assay Intraoperatively

EXPERIMENTAL

SLNs were tested by the OSNA assay Intraoperatively

Device: The OSNA assay

Interventions

SLN was defatted after SLNB. If the node weighed less than 100mg, the node was only assessed by histology postoperatively. If the node weighed more than 100mg, the node was sliced to equal blocks according to the length of short axis: If the length was less than 4mm, the node was sliced into two blocks along the long axis (a, b). Intraoperatively, the block a and b were tested by TIC, and the block a was prepared for OSNA. Postoperatively, the block b was assessed by histology. If the length was more than 4mm, the node was sliced into four blocks (a, b, c, d). Intraoperatively, all blocks (a, b, c, d) were tested by TIC, and the block a and c were prepared for OSNA.

SLNs were tested by the OSNA assay Intraoperatively

Eligibility Criteria

Age18 Years - 70 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • The breast cancer patients scheduled for SLNB.

You may not qualify if:

  • The patients who had undergone previous ipsilateral axillary surgery.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Breast Cancer Center, Shandong Cancer Hospital Affiliated to Shandong University

Jinan, 250117, China

RECRUITING

Related Publications (1)

  • Wang YS, Ou-yang T, Wu J, Liu YH, Cao XC, Sun X, Fu L, Liao N, Yang WT, Zhong WX, Lu AP. Comparative study of one-step nucleic acid amplification assay, frozen section, and touch imprint cytology for intraoperative assessment of breast sentinel lymph node in Chinese patients. Cancer Sci. 2012 Nov;103(11):1989-93. doi: 10.1111/cas.12001. Epub 2012 Oct 18.

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Study Officials

  • Yong-sheng Wang

    Shandong Cancer Hospital & Institute

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Direct of Breast Cancer Center

Study Record Dates

First Submitted

April 27, 2019

First Posted

May 3, 2019

Study Start

February 1, 2010

Primary Completion

February 1, 2020

Study Completion

August 1, 2020

Last Updated

May 3, 2019

Record last verified: 2019-05

Locations